13results about How to "Delay disease progression" patented technology

The invention discloses an overexpression vector of LAMP2B and application thereof, which can effectively delay the disease progress of DMD, and comprises: (a) an AAV vector which is an adeno-associated virus vector and has high muscle tissue targeting and low liver tropism; (b) a CMV (cytomegalovirus) promoter, wherein the CMV promoter is a cytomegalovirus promoter; (c) a coding sequence of an hLAMP2B gene, namely a coding sequence of a human LAMP2B gene, and the coding sequence of the hLAMP2B gene is operably linked to the CMV promoter; wherein the vector is configured to overexpress LAMP2B protein in muscular tissue, and the vector is self-complementary AAV, namely scAAV, the concept is ingenious, the novel AAV vector with high muscle transformation efficiency is utilized to deliver a complete LAMP2B gene (LAMP2B is a gene related to autophagy regulation) into muscle cells of all organs of a mouse (AAV-hLAMP2B for short), and the autophagy regulation function of the mouse is improved. The muscle tissue function of the mouse DMD disease model is comprehensively assisted to recover, and the disease progress of the DMD is delayed.

The invention discloses a traditional Chinese medicine monomer composition derived from chrysanthemum plants and used for treating diabetic retinopathy as well as a preparation method and application of the traditional Chinese medicine monomer composition. The traditional Chinese medicine monomer composition prepared from the chrysanthemum plant as the raw material is high in safety, small in side effect and definite in component and is prepared according to a specific ratio, and pharmacodynamic experiments prove that compared with an ethanol extract, the traditional Chinese medicine monomer composition is more remarkable in curative effect on diabetic retinopathy, and the curative effect of the traditional Chinese medicine monomer composition on diabetic retinopathy is better than that of a traditional Chinese medicine composition on diabetic retinopathy. The composition can improve the pathological state of diabetic retinopathy from multiple targets and multiple ways, specifically can inhibit body mass increase caused by high glucose, reduce blood glucose level, improve retinal tissue structure damage, recover retinal tissue thickness, inhibit retinal cell apoptosis and inflammatory response, reduce the expression level of HIF-1alpha and VEGF protein in retinal tissue, and can be used for treating diabetic retinopathy. Scientific basis and technical support are provided for research and development of novel drugs for treating the diabetic retinopathy, and important clinical significance and market application prospects are achieved.

The invention relates to the technical field of bioengineering, in particular to a targeting nanoparticle for treating acute respiratory distress syndrome as well as a preparation method and application of the targeting nanoparticle. Comprising the following steps: (1) combining MP peptide with DSPE-PEG2000-MAL through a maleimide-mercaptan reaction, dialyzing the obtained conjugate, washing, and freeze-drying, so as to obtain a DSPE-PEG2000-MP conjugate; and (2) mixing the conjugate, lipid, a pharmaceutical preparation and a solvent, removing the solvent to obtain a lipid film, hydrating the lipid film, and performing membrane extrusion to obtain the nanoparticles. The invention not only provides a novel efficient and safe ARDS treatment scheme, but also provides an innovative mode for the design of a nano-drug delivery system based on cell mediation. And due to the dual targeting capability, excellent anti-inflammatory efficiency and good biocompatibility, the nano-material has a wide prospect in clinical application.

This invention provides a method for controlling potato verticillium wilt using ABT rooting powder, comprising: fully dissolving ABT rooting powder in alcohol, diluting with distilled water, and setting aside; removing 2-week-old Désirée and Zhongshu 19 test-tube seedlings, cutting off the roots, soaking the base of the potato stems in ABT rooting powder, planting them in a hydroponic box, observing the growth of the potato roots, and selecting a suitable concentration of ABT rooting powder for later use; planting Désirée and Zhongshu 19 test-tube seedlings, and when the plants have grown to 4-6 true leaves, preparing a suspension of non-alfalfa Verticillium Vn011 spores and irrigating the base of the potato stems; irrigating the base of the potato stems with ABT rooting powder 3 days after inoculation with the pathogen; calculating the disease severity and disease index 20, 30, and 40 days after inoculation with the pathogen; harvesting potatoes 50 days after inoculation with the pathogen, measuring yield, and observing and statistically analyzing the growth of the potato roots. This invention utilizes ABT rooting powder to promote the rapid growth of potato roots and plants, thereby achieving the purpose of preventing and controlling potato verticillium wilt.

The present invention relates to the technical field of traditional Chinese medicine, and provides an application of a traditional Chinese medicine composition in the preparation of treating postmenopausal osteoporosis. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 25-35 parts of Glossy Privet Fruit, 10-20 parts of Morinda officinalis How, 10-20 parts of Drynaria fortunei (Kunze) J. Sm., and 5-15 parts of Alisma orientale (Sam.) Juz. Among them, Glossy Privet Fruit is the monarch drug, with a mild nature, being good at nourishing the liver and kidney, and replenishing yin and generating essence; Morinda officinalis How and Drynaria fortunei (Kunze) J. Sm. together serve as the ministerial drugs, and Alisma orientale (Sam.) Juz. serves as the assistant and guiding drug. The whole formula can achieve the effects of tonifying both yin and yang, tonifying without stagnation, and dispelling pathogenic factors and strengthening healthy qi.

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The invention discloses an application of a benzo-aza derivative in preparation of a medicine for preventing or treating atherosclerosis, the benzo-aza derivative is a compound with a chemical structure as shown in a formula I, or a pharmaceutically acceptable salt, a precursor or a metabolite of the compound, and in the formula I, X is halogen or H. The traditional Chinese medicine composition has the technical effects that the plaque stabilizing effect is obvious, the plaque composition is improved, the necrosis core area in the plaque is reduced, the total plaque load can be effectively reduced, the lesion progress is delayed / reversed, the dependence on lipid reduction is avoided, the treatment blank is filled, a brand new plaque stabilizing treatment strategy is provided, and the clinical problem of residual cardiovascular risks is expected to be solved. The safety is good, the organ specificity is high, and the whole body toxicity is low. The invention provides a new treatment normal form, new use of old medicines and large clinical transformation potential, and can be used as a supplement and enhancement of a basic therapy (such as statin lipid reduction) to form a combined treatment scheme of lipid reduction and spot stabilization, thereby realizing multi-channel cooperative control of atherosclerosis.

This invention provides a traditional Chinese medicine composition for treating androgenetic alopecia, formulated from the following raw materials in parts by weight: 1.5-3 parts of processed Polygonum multiflorum, 1.5-3 parts of Drynaria fortunei, 0.5-1.5 parts of Glycyrrhiza uralensis, 2.5-3 parts of raw Platycladus orientalis leaves, 2.5-3 parts of Salvia miltiorrhiza, 1.5-3 parts of Angelica sinensis, and 1-2 parts of Ligusticum chuanxiong. The above-mentioned traditional Chinese medicine composition is obtained by decocting and concentrating the herbs after soaking them in cold water for 20-30 minutes. This invention uses traditional Chinese medicinal materials that promote blood circulation, nourish blood and essence, and have anti-inflammatory and anti-allergic effects as raw materials. It has multiple effects, including improving blood circulation and nourishing hair follicles, thus curing hair loss from the root cause. The synergistic effect of the above-mentioned herbs not only nourishes hair but also prevents hair loss and moisturizes the skin.

This invention discloses the use of oligomycin A in the preparation of a drug for competitively inhibiting EphB3 to reverse lorlatinib resistance, belonging to the field of biomedical technology. This invention experimentally discovered that EphB3 is a key factor mediating lorlatinib resistance in lung cancer, and that existing oligomycin A can effectively reverse EphB3-mediated resistance by competitively binding to EphB3. Based on this, this invention protects the use of oligomycin A in the preparation of a drug for reversing lorlatinib resistance in tumors (especially ALK-positive non-small cell lung cancer). Simultaneously, this invention also protects a therapeutically effective pharmaceutical composition comprising oligomycin A and lorlatinib, and a non-therapeutic method for reversing cellular resistance to lorlatinib in vitro. This invention provides a novel and effective solution for overcoming lorlatinib resistance in clinical practice.

The application relates to an application of a traditional Chinese medicine composition in a drug for chronic obstructive pulmonary disease, characterized in that the traditional Chinese medicine composition comprises the following components in parts: Magnolia officinalis 1-100 parts, Strychnos ignatii 1-100 parts, Toddalia asiatica 1-100 parts, Ephedra 1-100 parts, Amygdalus 1-100 parts, Notopterygium 1-100 parts, Zingiber officinale 1-100 parts, Pogostemonis 1-100 parts, Perilla 1-100 parts, Atractylodes 1-100 parts, Poria cocos 1-160 parts, Atractylodes macrocephala 1-120 parts, Gypsum fibrosum 1-100 parts, Fructus Crataegi 1-100 parts, Fructus Junci 1-100 parts, Fructus Hordei 1-100 parts, Lumbricus 1-100 parts, Radix et Rhizoma Veratri 1-100 parts, Herba Eupatorii Fortunei 1-100 parts, Semen Lepidii 1-100 parts and Semen Platycladi 1-100 parts.

The application discloses macrophage membrane-coated methacrylated hyaluronic acid hydrogel microspheres and application, relates to the technical field of drug synthesis, and technical solution points are that a kind of macrophage membrane-coated methacrylated hyaluronic acid hydrogel microspheres EMM@HMs can efficiently neutralize key proinflammatory factors, the proinflammatory factor includes TNF-alpha and IL-1 beta, to relieve joint inflammation.It is good in the curative effect and biocompatibility in OA model, especially its effect in the regulation of macrophage polarization, inhibition of chondrocyte hypertrophy and neutralization of proinflammatory factors.EMM@HMs can not only significantly reduce inflammation by targeting the key link in the pathogenesis of OA, but also has the potential to delay disease progression, providing a new strategy with a breakthrough significance for the treatment of OA.

This invention discloses a CH@SHP099-NPs composite hydrogel, its preparation method, and its applications, belonging to the field of biomedical technology. Addressing the technical challenge of achieving long-term, safe, and precise metabolic intervention with SHP2, this invention constructs a hydrogel system composed of chondroitin sulfate and hyaluronic acid. This system can retain SHP099-loaded nanoparticles within the joint cavity, forming a long-acting intrasynovial drug library, thereby continuously inhibiting the SHP2-AMPK signaling axis. The CH@SHP099-NPs composite hydrogel prepared in this invention can effectively reprogram the metabolic state of macrophages, reduce glycolysis flux, restore synovial immune metabolic homeostasis, and significantly improve synovial inflammation, chondrocyte activity, and cartilage structural integrity in vivo. This invention proposes a mechanism-guided local delivery metabolic intervention strategy, which is expected to provide a new interventional approach for the treatment of osteoarthritis.

The invention discloses an application of spermidine and pharmaceutically acceptable salts thereof in preparation of drugs for treating DKD, which can significantly reduce UACR, present a dose-dependent trend, improve renal function indexes, reduce blood sugar level and improve renal histopathologic change, thereby alleviating diabetic nephropathy related kidney injury and delaying disease progression.